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Abstract
Background: Infectious intestinal disease (IID) is an important cause of morbidity in developed countries and a
frequent reason for general practitioner (GP) consultation. In recent years polymerase chain reaction (PCR) based
techniques have gradually replaced conventional enteropathogen detection techniques like microscopy and culture
in primary care patients suspected of IID. PCR features testing of multiple enteropathogens in a single faecal sample
with shorter turnaround times and greater sensitivity compared to conventional techniques. However, the
associated costs and benefits have not been quantified. Furthermore, primary care incidence and prevalence
estimates of enteropathogens associated with IID are sparsely available and predominantly based on
conventional techniques. The PROUD-study (PCR diagnostics in Outpatients with Diarrhoea) determines: 1)
health (care) effects and 2) cost-effectiveness of PCR introduction in primary care patients suspected of IID; 3)
occurrence of major enteropathogens in primary care patients suspected of IID.
Methods: A before-after cohort study will be performed of patients with suspected IID consulting a GP in
the Utrecht General Practitioner Network (UGPN), covering the before period (2010–2011) with conventional
testing and the after period (2013–2014) with PCR testing. Prospective study data on patient characteristics
and primary outcome measures (i.e. healthcare use and disease outcome) will be collected from electronic
patient and laboratory records in 2015 and 2016. The effect of PCR introduction is investigated by comparing
the primary outcome measures and their associated healthcare costs between the conventional period and
the PCR period, and is followed by a cost-effectiveness analysis. To determine the occurrence of enteropathogens
associated with IID in primary care, routine care faeces samples from the year 2014 will be screened using PCR.
Discussion: The PROUD-study will quantify the costs and effects of the introduction of PCR techniques for
enteropathogens in primary care patients suspected of IID and generate up-to-date and sensitive estimates of
enteropathogen occurrence among primary care patients.
Keywords: PCR, Molecular diagnostics, Gastroenteritis, Infectious intestinal disease, Diarrhoea enteropathogens,
Primary care, General practitioner, Faeces testing, Economic evaluation
Background
Despite high hygienic standards and socioeconomic
level, infectious intestinal disease (IID) remains a major
cause of morbidity in developed countries, with a re-
ported incidence of 19–83 cases/100 person years [1–5].
The direct healthcare costs for all cause gastroenteritis
in the Netherlands have almost doubled in the last
decade and are estimated at €147 million per year [6].
In primary care IID is among the most frequent rea-
sons for consultation [7], but generally requires support-
ive treatment only as most IID episodes are self-limiting.
According to Dutch guidelines, microbiological faeces
testing to detect the causative pathogen is only recom-
mended for high-risk patients that may require anti-
microbial treatment or pose a substantial transmission
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risk to others, such as healthcare or food-production
workers.
In recent years, molecular based faeces testing using
Polymerase Chain Reaction (PCR) techniques have be-
come available for primary care use, replacing conven-
tional microbiological diagnostic techniques like culture
and microscopy. PCR faeces testing allows detection of
multiple enteropathogens in a single sample with shorter
turnaround times and greater sensitivity compared to
conventional methods [8, 9]. Implementation of PCR
initially requires a substantial investment, but can poten-
tially lead to an overall cost reduction by extensive auto-
mation. Due to its potential added clinical value,
primary care diagnostic laboratories in the Netherlands
have increasingly replaced conventional techniques by
PCR testing. To what extent the introduction of PCR in
primary care has affected detection rates of causative
enteropathogens, disease outcome and the use of health-
care resources, such as antibiotic prescribing and faeces
testing has not yet been determined. Before further
implementation of PCR faeces testing in primary care
can be recommended, it is crucial to identify its ef-
fects and to evaluate if PCR faeces testing in patients
with suspected IID is cost-effective in comparison to
conventional testing.
Here the study design and rationale of the PROUD-
study (PcR faeces testing in OUtpatients with Diarrhoea),
a primary care based study on IID and PCR introduction
in the Netherlands, is described.
Methods
Objectives
The primary objectives of the PROUD study are:
1. To determine the effects of PCR introduction for
enteropathogen detection in primary care on
important aspects of healthcare use among patients
consulting for suspected IID, including the rate of
microbiological faeces testing, (antibiotic) drug
prescription, reconsultation and referral to medical
specialist, and on their disease outcome, including
IID duration and confirmed enteropathogens.
2. To determine the cost-effectiveness of PCR faeces
testing in primary care in comparison to conven-
tional testing taking both a program perspective,
including only testing costs, and a healthcare payer
perspective, including both testing costs and other
direct healthcare costs.
3. To determine the occurrence of major
enteropathogens as detected by PCR testing among
primary care patients with suspected IID.
Secondary objectives investigated in the PROUD study
are outlined in Additional file 1.
Study design
To evaluate the introduction of PCR faeces testing and
improve clinical management of IID in primary care, a
before-after cohort study will be performed, including
prospective data of a 2-year ‘before‘period with conven-
tional testing and a 2-year ‘after’ period with PCR test-
ing, and excluding a one-year wash-in period in which
PCR testing is introduced. A before-after study design is
adopted while the novel diagnostic technique (PCR) is
already implemented in the region of our institute.
Besides this reason, a prospective randomized design
would require substantial human and financial resources
in order to recruit sufficient patients to study the pri-
mary objectives. The main advantage of a before-after
study design is that it prevents interference with usual
clinical care (i.e. GPs are not aware of the on-going
study) and laboratory logistics, and the use of prospect-
ive study data, therefore representing routine clinical
practice.
To determine primary care occurrence of major enter-
opathogens as detected by PCR faeces testing, a nested
1-year microbiological study with full panel enteropatho-
gens PCR testing for IID causing bacteria, parasites and
viruses, will be performed.
Study population
The study population includes patients registered with a
general practice affiliated with both the Utrecht General
Practitioner Network (UGPN) and Saltro Diagnostic
Center. The UGPN database contains pseudonymous
routine healthcare data extracted from the Electronic
Medical Records (EMR) of 225 GPs in metropolitan Ut-
recht with approximately 330,000 patients enlisted (in
2013). The general practices contributing to the database
contain a representative sample of the Dutch population.
The GPs working in participating practices are trained
in correct use of International Classification of Primary
Care (ICPC) coding and have on average 10 years’ experi-
ence in systematic coding of disease episodes [10]. Saltro
Diagnostic Center is a large primary care laboratory oper-
ating in the UGPN service area and replaced conventional
enteropathogen testing by PCR in April 2012.
In the before-after study, subjects eligible for inclusion
are patients consulting a UGPN practitioner with sus-
pected IID in the before period (2010–2011) or after
period (2013–2014) (Fig. 1, population 1a and 1b). Sus-
pected IID is defined as a consultation coded with ICPC
D11 (diarrhoea), D70 (gastrointestinal infection) or D73
(suspected infectious gastroenteritis). A one-year wash-
in period (2012) is excluded from the analysis to account
for adaptation to the new PCR strategy.
In the microbiological study, all patients referred by an
UGPN physician to Saltro Diagnostic Center for micro-
biological faeces testing in 2014 are included (Fig. 1,
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population 3a and 3b). Therefore, the microbiological
study population includes all PCR tested UGPN patients,
regardless of the assigned ICPC codes.
Measurements before-after study
Clinical patient data
For each patient with an episode of suspected IID, rou-
tine care data on patient demographics, healthcare use
and disease outcome are extracted from the EMR. Pa-
tient demographics include age, gender, ICPC coded co-
morbidities, immunocompromised status (e.g. chronic
immunosuppressive therapy, chronic renal and/or liver
disease, current malignancy and chemotherapy) and
other assumed IID risk factors present at the first time
of consultation for suspected IID (Additional file 2).
Healthcare use per disease episode (defined as a period
between the first and last consultation for the same indi-
cation with a minimum of 60 days) includes drug pre-
scriptions, assigned ICPC codes (Additional file 3), and
the number and type of consultations per episode. Disease
outcome includes duration per episode and enteropatho-
gens identified. Mortality is not measured, as it is not part
of the UGPN data and not retrievable via Municipal Ad-
ministration (GBA), since direct identification of included
subject is not possible.
Linkage of clinical patient data with faeces test data
To link (clinical) patient data with corresponding micro-
biological test results, all patients identified in the UGPN
database are linked with the laboratory records from
Saltro Diagnostic Center by a ‘trusted third party’ using
a pseudonimization procedure in accordance with the
Dutch Health Insurance Portability and Accountability
Act of 1996.
Faeces testing
Results for 14 enteropathogens (Table 1) of patients with
suspected IID who underwent conventional faeces test-
ing (microscopy, culture and/or enzyme immunoassay
[EIA]) in the before period and with primarily PCR test-
ing in the after period, are gathered. A routine culture
attempt is performed on all positive bacterial PCR tests.
In principle, this allows us to obtain the corresponding
isolates and to perform further serologic, relevant
phenotypic or genetic typing. For both methods the rela-
tive sensitivity, specificity and efficiency will be deter-
mined, also proving a basis for the cost-effectiveness
analysis (objective 2).
Measurements for microbiological study
For the microbiological study (objective 3), faecal samples
sent for microbiological testing from all participating
Fig. 1 Sources and composition of study population of ‘before’ and ‘after’ cohorts. Blue circle: Clinical patient data from Utrecht General
Practitioner Network (UGPN) of 2010–2014. Purple circle: faeces testing result from Saltro Diagnostic Center of 2010–2014. 1/2a: UGPN patient
with a faeces test. 1/2b: UGPN patient without faeces test. 1a/b: UGPN patients with a coded episode of suspected Infectious Intestinal Disease
(IID). 2a/b: UGPN patients without a coded episode of suspected IID. 3a/b: Patients included in microbiological study with/without a coded
episode of suspected IID
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UGPN practices to Saltro Diagnostic Center in 2014 are
tested with PCR (Additional file 4) for 19 of the entero-
pathogens as described in Table 2.
Outcome measures
In the before-after study the outcome measures are:
healthcare use; operationalized as the proportions of fae-
ces testing, (antibiotic) drug prescribing, number of GP
consultations per disease episode and specialist referrals
during each period among patients consulting their GP
for suspected IID, and disease outcome; operationalized as
confirmed IID indicated by a positive test result and dis-
ease duration defined as the number of days between the
first and the last consultation of the episode (objective 1).
In the economic evaluation, several outcome measures
for costs and effects are included. For costs healthcare
costs, testing costs and total costs (healthcare and testing
costs) per episode and in total, are included. Included
effects per disease episode are the proportion of faeces
testing, detected relevant enteropathogens, antibiotic
prescription, reconsultation and referral in the before and
after periods. To compare conventional testing to PCR
testing (objective 2), the difference in costs will be com-
pared to a difference in the mentioned effects and
expressed as a cost-effectiveness ratio (CER), for example
the additional costs per detected relevant enteropathogen.
In the microbiological study, the outcome measure is
the absence or presence per enteropathogen in the
collected faeces samples detected by PCR (objective 3).
Statistical analysis
Objective 1
To estimate the effect of PCR introduction on healthcare
use and disease outcome the above mentioned outcome
measures are compared between the patient cohorts in
the before and after period, taking into account potential
differences in patient characteristics and comorbidities
between the two cohorts (Additional file 2). Differences in
continuous and categorical outcome measures are quanti-
fied by Mann–Whitney U tests and Fisher’s exact tests,
Table 1 IID causing enteropathogens (n = 14) included in “before-after” study
Enteropathogen Before test After test
Test method Identification method Test method Identification method
Campylobacter spp. Culture Campylobacter selective agar, hippurate
hydrolysis identification
PCR LightMix Modular Gastro Bacteria
Clostridium difficile EIA ImmunoCard Toxine A/B EIA ImmunoCard Toxine A/B
Salmonella spp. Culture XLD agar, Vitek identification PCR TIB MOLBIOL LightMix Modular Gastro Bacteria
Shigella spp. Culture XLD agar, Vitek identification PCR TIB MOLBIOL LightMix Modular Gastro Bacteria
Plesiomonas spp Culture XLD agar, Vitek identification PCR TIB MOLBIOL LightMix Modular Gastro Bacteria
Yersinia spp. Culture CIN agar, Vitek identification PCR TIB MOLBIOL LightMix Modular Gastro Bacteria
Blastocystis hominis Microscopy Direct with accumulation (Ridley) PCR TIB MOLBIOL LightMix Modular Gastro Parasites
Cryptosporidium spp. Microscopy Direct with accumulation (Ridley) PCR TIB MOLBIOL LightMix Modular Gastro Parasites
Dientamoeba fragilis Microscopy TFT PCR TIB MOLBIOL LightMix Modular Gastro Parasites
Entamoeba histolytica Microscopy Direct with accumulation (Ridley) PCR TIB MOLBIOL LightMix Modular Gastro Parasites
Giardia spp. Microscopy Direct with accumulation (Ridley) PCR TIB MOLBIOL LightMix Modular Gastro Parasites
Adenovirus 40/41 ICS R-Biopharm RIDA Quick Adeno/Rotavirus ICS R-Biopharm RIDA Quick Adeno/Rotavirus
Norovirus ICS R-Biopharm RIDA Quick Nonvirus ICS R-Biopharm RIDA Quick Nonvirus
Rotavirus ICS R-Biopharm RIDA Quick Adeno/Rotavirus ICS R-Biopharm RIDA Quick Adeno/Rotavirus
CIN cefsulodin-irgasan-novobiocin, EIA enzyme immunoassay, ICS immunochromatographic strip, TFT triple faeces test, XLD xylose-lysine-deoxycholate
Table 2 IID causing enteropathogens (n = 19) included in PCR testing for microbiological study
Enteropathogen PCR assay PCR system Positive test
Campylobacter spp., Salmonella spp., Shigella spp., Plesiomonas spp.,
Yersinia spp.
TIB MOLBIOL LightMix® Modular Gastro
Bacteria
LightCycler 480 II Ct <45
Clostridium difficile R-Biopharm RIDA®GENE Clostridium difficile
Toxin A/B
LightCycler 480 II Ct <45
EHEC/STEC, EPEC R-Biopharm RIDA®GENE E.Coli Stool Panel 1 LightCycler 480 II Ct <45
Blastocystis hominis, Cryptosporidium spp., Dientamoeba fragilis,
Entamoeba histolytica, Giardia spp.
TIB MOLBIOL LightMix® Modular Gastro
Parasites
LightCycler 480 II Ct <45
Adenovirus 40/41, Astrovirus, Norovirus, Rotavirus, Sapovirus Laboratory Developed Test ABI 7500 Ct <45
EHEC enterohaemorrhagic Escherichia coli, STEC shiga toxin-producing Escherichia coli, EPEC enteropathogenic Escherichia coli
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respectively. To assess the independent effect of the intro-
duction of PCR on the proposed outcome measures, an
interrupted time series analysis is performed incorporating
potential confounding variables including age, gender,
policy deductibles of health care insurance and patient co-
morbidities (DM, COPD, asthma, cardiovascular diseases,
inflammatory bowel disease [IBD], irritable bowel syn-
drome [IBS], and immunocompromising disease and
medication). This type of analysis uses segmented regres-
sion to measure changes in level and slope in the before
period compared to the after period to control for secular
trends in the data [11], making adjustment for individual-
level characteristics unnecessary [12].
Objective 2
Healthcare costs are calculated by multiplying the ex-
tracted healthcare resources used with their unit cost
prices according to the Dutch guidelines [13, 14]. Test
costs are calculated based on the unit cost prices accord-
ing to the Dutch Healthcare Authority (NZA) tariffs,
material and overhead costs for conventional and PCR
testing. All costs are expressed for the year 2015 and
considered both undiscounted and discounted (i.e. 4 %).
To determine the cost-effectiveness of PCR testing com-
pared to conventional faeces testing, a cost-effectiveness
analysis (CEA) is performed from both a program per-
spective (i.e. testing costs only) and from a healthcare
payer perspective (i.e. healthcare costs and testing costs)
respectively, and expressed as CERs. Subgroup analysis
is performed for various age groups and for all patho-
gen-groups (i.e. bacteria, parasites and virus testing). Fi-
nally, cost-effectiveness for scenarios with different levels
for PCR costs and cut-off values for PCR sensitivity (Ct-
values) are evaluated. Adjustment for potential confound-
ing variables is performed as described above. It is as-
sumed that within the study periods no differences in
healthcare setting, like changes in personnel (e.g. GP) and
background changes in GP population, occur that signifi-
cantly influence the results.
Objective 3
To determine the incidence of enteropathogens in pri-
mary care patients suspected of IID as detected by PCR
testing, the proportion and 95 % CI of individual and
combined infections are calculated. First using the num-
ber of patients with microbiological testing performed as
the denominator, and secondly by extrapolation to the
general population of patients that visit the GP with
suspected IID through standardization by age, gender,
patient comorbidities (as described under objective 1)
and episode ICPC code according to the distribution
in the complete cohort of 2014.
Power calculations
We assessed the statistical power of before-after study,
covering a 2-year “before” period with conventional test-
ing and a 2-year “after” period with PCR testing and ex-
cluding a one-year wash-in period in between. These
calculations were based on the minimal detectable differ-
ence between the two study periods for two clinically
important outcomes: the proportions of IID patients in
whom diagnostic testing is performed and the propor-
tion of prescribed antibiotics. Two-tailed Fisher’s exact
tests were performed using a significance level of 5 %
and a power of 90 %. Based on previous evidence it is
anticipated that between 4,615 and 11,539 of the
330,000 UGPN patients annually consulted their GP
with suspected IID (Fig. 1, population 1a/b) [1], of which
around 12 % (554–1,385) are tested for enteropathogens
in the before period (Fig. 1, population 3a) [15]. The
minimal detectable difference in proportion of diagnos-
tic tests performed between the two periods ranges
between 1 to 1.6 % depending on the actual number of
suspected IID cases. Anticipating a 27 % antibiotic pre-
scription rate among patients with suspected IID in the
conventional period, around 9,230–23,078 patients per
year were expected to receive an antibiotic prescription
[15]. Depending on the actual number of suspected IID
cases, the minimal detectable difference in antibiotic
prescribing rates ranged between 1.3 and 2.1 %.
For the one-year microbiological study with PCR test-
ing, the achievable precision in estimates for entero-
pathogen proportions was evaluated through exploration
of the 95 % confidence interval (CI) widths over a range
of plausible enteropathogen proportions. As described
above we expected at least 554–1,385 UGPN patients
per year with an episode of suspected IID and a faeces
test. The width of the CI ranged between ±0.2 % for the
least expected pathogen (Shigella spp.) and based on the
largest estimated sample size, to ±3.4 % for the most
prevalent pathogen (Blastocystis hominis) and smallest
sample size (Additional file 5).
It was concluded that a before-after study including
two periods of 2 years and microbiological study includ-
ing a 1-year period of PCR testing were sufficient to
study our primary objectives.
Ethical approval
The act on medical research involving human subjects
does not apply to this study and therefore official ap-
proval of this study by the Institutional Review Board
(IRB) of the University Medical Center Utrecht was not
required (IRB-number: 13–480).
Discussion
The PROUD study will quantify the effects of the intro-
duction of PCR faeces testing and its cost-effectiveness
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in primary care patients with suspected IID, and may
guide further large-scale implementation of PCR testing
in primary care. It will also describe the epidemiology of
IID and aetiology of enteropathogens detected with
PCR, both relevant for clinical practice and healthcare
policy making.
Conventional and molecular techniques for the detec-
tion of enteropathogens exhibit different test characteris-
tics, where PCR-based testing has a lower turnaround
time and its increased sensitivity may yield 1.4 to 3-fold
higher detection rate [8, 9, 16, 17]. The latter leads to a
higher diagnostic yield, but may also detect non-relevant
microorganisms. It is therefore important to include the
effects of the test results on patient management in the
evaluation of introducing PCR-based testing, rather than
exclusively focusing on the technical performance of
these diagnostic techniques.
Strengths
The use of routine study data and a before-after study
design prevents interference with routine clinical care in
primary care patients with suspected IID, excluding bias
introduced by an observer effect [18]. However, the
before-after study design may be susceptible to bias, but
has previously been used successfully to evaluate the
cost-effectiveness of an infection control program to re-
duce nosocomial respiratory syncytial virus transmission
and an intervention to reduce the spread of influenza
during the H1N1 pandemic [19, 20].
The possibility to use the UGPN database, including
330,000 patients, allows us to study sufficient numbers
of patients in a relatively short time period. Naturally,
our study domain is restricted to patients consulting
their GP for IID, which we consider the relevant popula-
tion this research question. Lastly, the use of a third
trusted party enables merging of patient data on an indi-
vidual level and ensures the anonymity of included
patients.
Limitations
Ideally a randomised controlled trial comparing effects
between two diagnostic strategies without extraneous
(other than the diagnostic strategy) factors would have
been performed. However, a prospective randomised
design would require substantial human and financial
resources in order to recruit sufficient patients to study
the primary objectives and exceeds the available budget.
Moreover, as PCR faeces testing was already imple-
mented in routine practice when initiating the PROUD
study, a comparison to conventional techniques was
logistically unfeasible.
In the economic evaluation, a restricted perspective
has to be taken, as we only have information on testing
costs and potential savings in healthcare costs in primary
care. Potential positive monetary and health effects due
to, for example reduced hospitalization, earlier detection
of an outbreak leading to reduced monitoring costs and
the prevention of disease complications (e.g. sepsis,
sequelae) through timely diagnosis and appropriated
treatment were not included as this information is
lacking in the consulted databases. Therefore, this
economic evaluation will lead to conservative CER es-
timates, but will resemble the costs and effects that
are relevant for the primary care domain.
Furthermore, a one-year microbiological study will po-
tentially be more prone to fluctuations when compared
to studies including multiple years. Yet, yearly variation
is mainly observed for enteric viruses, whereas for more
clinically relevant bacterial and parasitic enteropatho-
gens fluctuations are less common.
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